Summary
Interactions between a selective catechol-O-methyltransferase (COMT) inhibitor OR-462 and a monoamine oxidase (MAO)-A inhibitor clorgyline were studied measuring concentrations of L-dopa, dopamine and their metabolites in the rat hypothalamus and striatum after administration of levodopa/carbidopa (15/30 mg/kg i.p.). Part of the experiments were performed in rats pretreated with 6-OH-dopamine (6-OHDA) intracerebroventricularly (i.c.v.) to determine whether changes in dopamine metabolism occurred inside or outside catecholaminergic neurons. OR-462 was an effective COMT inhibitor at the doses 3 and 30 mg/kg i.p. Inhibition of 3-O-methyldopa (3-OMD) formation from L-dopa was reflected in the hypothalamus (45–81% decrease) and striatum (87–88% decrease), since 3-OMD penetrates the blood-brain barrier. Homovanillic acid (HVA) was decreased only in the striatum at 30 mg/kg of OR-462. Clorgyline (8 and 32 mg/kg i.p.) decreased 3,4-dihydroxyphenylacetic acid (DOPAC) formation in the hypothalamus and striatum by 61–91%. When given together, OR-462 and clorgyline elevated hypothalamic dopamine levels 3.2–4.6-fold, but striatal dopamine only 1.3–1.9-fold. The formation of 3-OMD and DOPAC remained suppressed and even brain HVA levels were decreased by 51–97%. 6-OHDA treatment decresed striatal and hypothalamic dopamine by 50% and noradrenaline by 75%. In these animals levodopa/carbidopa increased brain L-dopa 2.4–4-fold, those of 3-OMD 1.2–1.7-fold compared to intact animals, but the synthesis and metabolism of dopamine and the effects of COMT and MAO inhibitors were not significantly changed. Levodopa/carbidopa treatment decreased significantly prolactin and thyrotropin levels in serum but none of the additional treatments changed this action.
Similar content being viewed by others
References
Buu N, Angers M (1987) Effect of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain. Biochem Pharmacol 36: 1731–1735
Cedarbaum JM (1987) Clinical pharmacokinetics of antiparkinsonian drugs. Clin Pharmacokinet 13: 141–178
Cuello AC, Shoemaker WJ, Ganong WJ (1974) Effect of 6-hydroxydopamine on hypothalamic norepinephrine and dopamine content, ultrastructure of the median eminence and plasma corticosterone. Brain Res 78: 57–69
Dousa MK, Tyce GM (1988) Free and conjugated plasma catecholamines, DOPA and 3-O-methyldopa in humans and various animal species. Proc Soc Exp Biol Med 188: 427–434
Dzoljic MR, Bruinvels J, Bonta IL (1977) Desynchronization of electrical activity in rats induced by deprenyl — an inhibitor of monoamine oxidase B-and relationship with selective increase of dopamine and β-phenylalanine. J Neural Transm 40: 1–12
Fix JA, Alexander J, Cortese M, Engle K, Leppert P, Repta AJ (1989) Short-chain alkyl esters of L-dopa as prodrugs for rectal absorption. Pharm Res 6: 501–505
Glowinsky J, Iversen LL (1966) Regional studies on catecholamines in the rat brain. I. The disposition of3H-norepinephrine,3H-dopamine and3H-dopa in various regions of the brain. J Neurochem 13: 655–669
Guldberg HC, Marsden CA (1975) Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev 27: 135–206
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297
Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandler M (eds) Advances in biochemical psychopharmacology, vol 5. Raven Press, New York, pp. 393–408
König JFR, Klippel RA (1963) The rat brain. A stereotaxic atlas of the forebrain and lower parts of the brain stem. Williams and Wilkins, Baltimore
Kopin IJ (1985) Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37: 333–364
Lindén I-B, Nissinen E, Etemadzadeh E, Kaakkola S, Männistö PT, Pohto P (1988) Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. J Pharmacol Exp Ther 247: 289–293
Lloyd KG, Hockman CH, Davidson L, Farley IJ, Hornykiewicz O (1980) Kinetics of L-dopa metabolism in the caudate nucleus of cats with ventromedial lesions. J Neural Transm [Suppl] 16: 33–44
Männistö PT (1983) Central regulation of thyrotropin secretion in rats: methodological aspects, problems and some progress. Med Biol 61: 92–100
Männistö PT, Kaakkola S, Nissinen E, Lindén I-B, Pohto P (1988) Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci 43: 1465–1471
Männistö PT, Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 10: 54–56
Männistö PT, Mattila J, Kaakkola S (1981) Possible involvement of nigrostriatal dopamine system in the inhibition of thyrotropin secretion in the rat. Eur J Pharmacol 76: 403–409
McKenzie JM (1958) The bioassay of thyrotropin in serum. Endocrinology 63: 372–383
Moore KE, Demarest KT (1982) Tuberoinfundibular and tuberohypophyseal dopaminergic neurons. Front Neuroendocrinol 7: 161–190
Nicoll CS (1967) Bio-assay of prolactin. Analysis of the pigeon crop-sac response to local prolactin injection by an objective and quantitative method. Endocrinology 641: 641–655
Nissinen E, Lindén I-B, Schultz E, Kaakkola S, Männistö PT, Pohto P (1988a) Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur J Pharmacol 153: 263–269
Nissinen E, Tuominen R, Perhoniemi V, Kaakkola S (1988b) Catechol-O-methyltransferase activity in human and rat small intestine. Life Sci 42: 2609–2614
Porter CC, Watson LS, Titus DC, Toturo JA, Byer SS (1962) Inhibition of dopa decarboxylation by the hydrazino analog of α-methyldopa. Biochem Pharmacol 11: 1067–1077
Shoemaker WS, Schlumpf M (1977) Diencephalic dopamine cell groups: correlations with endocrine status. In: Costa E, Gessa GL (eds) Advances in biochemical psychopharmacology, vol 16. Raven Press, New York, pp. 359–367
Tuomisto J, Männistö PT (1985) Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 37: 249–332
Wagner J, Vitali P, Palfreyman MG, Zraika M, Huot S (1982) Simultaneous determination of 3,4-dihydroxyphenylalanine, 5-hydroxytryptophan, dopamine, 4-hydroxy-3-methoxyphenylalanine, norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, serotonin, and 5-hydroxyindoleacetic acid in rat cerebrospinal fluid and brain by high-performance liquid chromatography with electrochemical detection. J Neurochem 38: 1241–1254
Yang HYT, Neff NH (1974) The monoamine oxidase of brain: selective inhibition with drugs and consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 189: 733–740
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Männistö, P.T., Tuomainen, P., Toivonen, M. et al. Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats. J Neural Transm Gen Sect 2, 31–43 (1990). https://doi.org/10.1007/BF02251244
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02251244